Core Viewpoint - The company, 联邦制药, announced a mid-term dividend of HKD 0.17507 per share, which will be distributed on October 15, 2025, for the six months ending June 30, 2025 [1] Group 1 - The mid-term dividend is set at HKD 0.17507 per share [1] - The dividend distribution date is scheduled for October 15, 2025 [1] - The dividend pertains to the financial period ending June 30, 2025 [1]

Group 1 - The company, 联邦制药 (03933), announced a mid-term dividend of HKD 0.17507 per share, which will be distributed on October 15, 2025 [1] - The dividend pertains to the six-month period ending June 30, 2025 [1]

EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 董事會成員包括執行董事：蔡海山先生、梁永康先生、蔡紹哲女士、方煜平先生、鄒鮮紅女士及朱蘇燕女士；以及獨立非執行董 事：張品文先生、宋敏教授及傅秋實博士 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 聯邦制藥國際控股有限公司 | | 股份代號 | 03933 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年六月三十日止六個月中期股息 | | 公告日期 | 2025年8月28日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 | 公告兌換 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 ( 於開曼群島註冊成立的有限公司 ) (股份代號 : 3933) 茲提述聯邦制藥國際控股有限公司（「本公司」）日期為二零二五年八月二十八日的公告，其 中包括宣派截至二零二五年六月三十日止六個月的中期股息每股人民幣16分。 應派發給股東的中期股息將折算為港幣支付。以兌換匯率人民幣1.00元相當於港幣1.094190元 計算，中期股息將以每股港幣0.175070元派發。 預期中期股息將於二零二五年十月十五日派發予於二零二五年九月三十日名列本公司股東名 冊的股東。 承董事會命 聯邦制藥國際控股有限公司 主席 蔡海山 香港，二零二五年十月二日 於本公告日期，董事會成員包括執行董事：蔡海山先生、梁永康先生、蔡紹哲女士、方煜平 先生、鄒鮮紅女士及朱蘇燕女士；以及獨立非執行董事：張品 ...

截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 聯邦制藥國際控股有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03933 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,800,000,000 | HKD | | 0.01 | HKD | | 38,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 3,800,000,000 | HKD | | 0.01 | HKD | | 38,000,000 | 本月底法定/註冊股本總額： HKD 38,000,000 股份發行人及根據《上市規則》第十九B ...

Core Viewpoint - The announcement highlights the approval of a clinical trial application for UBT37034, a novel peptide receptor agonist targeting overweight or obesity, indicating a significant advancement in the company's product pipeline and potential market competitiveness [1] Group 1: Clinical Trial Approval - The clinical trial registration application for UBT37034 received implied approval from the National Medical Products Administration of China, with acceptance number CXHL2500772 [1] - UBT37034 is designed to selectively act on the neuropeptide Y2 receptor to aid in weight reduction [1] Group 2: Preclinical and Regulatory Milestones - Preclinical studies in various animal models demonstrated that UBT37034, in combination with GLP-1 analogs, can significantly reduce body weight [1] - The Investigational New Drug (IND) application for UBT37034 was approved by the U.S. Food and Drug Administration on July 2025, with IND number 175188 [1] Group 3: Future Outlook - The company aims to continue its focus on new product development to enhance its competitiveness and creativity in the biopharmaceutical industry [1] - There is an expectation that these advancements will generate greater returns for the company and its shareholders [1]

Core Viewpoint - Federal Pharmaceutical (03933) has received implied approval for clinical trials of its injectable drug UBT37034 for overweight or obesity indications from the National Medical Products Administration of China [1] Group 1: Drug Development - UBT37034 is a novel peptide receptor agonist that selectively targets neuropeptide Y2 receptors to aid in weight loss [1] - Preclinical studies in various animal models indicate that UBT37034, when used in conjunction with GLP-1 analogs, significantly reduces body weight [1] - The new drug clinical trial application (IND) for UBT37034 regarding overweight or obesity indications was approved by the U.S. Food and Drug Administration on July 2025, with IND number 175188 [1] Group 2: Future Outlook - The company will continue to focus on new product development and aims to enhance its competitiveness and creativity in the biopharmaceutical industry [1] - The anticipated advancements are expected to generate greater returns for the company and its shareholders [1]

Core Viewpoint - Federal Pharmaceutical (03933) announced that its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., received implicit approval from the National Medical Products Administration of China for the clinical trial registration application of its innovative drug UBT37034 for overweight or obesity indications [1] Group 1: Product Development - UBT37034 is a novel peptide receptor agonist that selectively targets neuropeptide Y2 receptors to aid in weight reduction [1] - Preclinical studies in various animal models indicate that UBT37034, when used in conjunction with GLP-1 analogs, significantly reduces body weight [1] - The new drug clinical trial application (IND) for UBT37034 regarding overweight or obesity indications was approved by the U.S. Food and Drug Administration in July 2025, with IND number 175188 [1] Group 2: Future Outlook - The company will continue to focus on new product development and aims to enhance its competitiveness and creativity in the biopharmaceutical industry [1] - The anticipated advancements in product development are expected to generate greater returns for the company and its shareholders [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 本公告乃由聯邦制藥國際控股有限公司（「本公司」）自願發出。 本公司董事會欣然公佈，於二零二五年九月二十九日，本公司全資附屬公司聯邦生物科技 （珠海橫琴）有限公司自主研發的 1 類創新藥注射用 UBT37034 關於超重或肥胖適應症的 臨 床 試 驗 註 冊 申 請 獲 得 中 國 國 家 藥 品 監 督 管 理 局 臨 床 試 驗 默 示 許 可 ， 受 理 號 為 CXHL2500772。 UBT37034 是一款新型多肽類受體激動劑，可通過選擇性作用於神經肽 Y2 受體減輕體重。 臨床前多種動物模型研究結果顯示，UBT37034 與 GLP-1 類似物聯用能夠顯著降低體重。 此外，UBT37034 注射液關於超重或肥胖適應症的新藥臨床試驗申請（「IND」）已於二零二 ...

The United Laboratories International Holdings Limited 聯 邦 制 藥 國 際 控 股 有 限 公 司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島成立之有限公司） (Stock code 股份代號: 3933) NOTIFICATION LETTER 通知信函 Dear Non-registered holder(Note 1) , The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at www.tul.com.hk and the HKExnews' website at www.hkexnews.hk, or the arranged printed form(s) of Current Corporate Communication is enclosed (if appl ...